2.74

2.49% -0.07

After Hours: 2.75 0.010 +0.36%

Mereo Biopharma Group Plc ADR (MREO)

Overview News Price History Option Chain Discussions Forecast

Mereo Biopharma Group Plc ADR stock is currently priced at $2.74, with a 24-hour trading volume of 562.55K. It has seen a -2.49% decreased in the last 24 hours and a -7.12% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.76 pivot point. If it approaches the $2.69 support level, significant changes may occur.

Previous Close:

$2.81

Open:

$2.81

24h Volume:

562.55K

Market Cap:

$384.31M

Revenue:

$10.00M

Net Income/Loss:

$-29.47M

P/E Ratio:

-9.0879

EPS:

-0.3015

Net Cash Flow:

$-21.55M

1W Performance:

+3.79%

1M Performance:

-7.12%

6M Performance:

+65.06%

1Y Performance:

+122.76%

1D Range:

$2.73

$2.81

52W Range:

$0.9201

$4.36

Mereo Biopharma Group Plc ADR Stock (MREO) Company Profile

Name

Mereo Biopharma Group Plc ADR

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

44 33 3023 7300

Address

1 Cavendish Place, Fourth Floor, London

Employee

Twitter

@MereoBioPharma

Next Earnings Date

2024-05-23

Latest SEC Filings

MREO's Discussions on Twitter

Mereo Biopharma Group Plc ADR Stock (MREO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-13-23	Resumed	BTIG Research	Buy
Aug-12-22	Initiated	Cantor Fitzgerald	Overweight
May-05-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Needham	Buy

Mereo Biopharma Group Plc ADR Stock (MREO) Latest News

MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

Zacks Investment Research

Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday

Benzinga

Mereo Biopharma Group Plc ADR Stock (MREO) Financials Data

Mereo Biopharma Group Plc ADR (MREO) Revenue 2024

MREO reported a revenue (TTM) of $10.00 million for the quarter ending December 31, 2023.

Mereo Biopharma Group Plc ADR (MREO) Net Income 2024

MREO net income (TTM) was -$29.47 million for the quarter ending December 31, 2023, a -271.57% decrease year-over-year.

Mereo Biopharma Group Plc ADR (MREO) Cash Flow 2024

MREO recorded a free cash flow (TTM) of -$21.55 million for the quarter ending December 31, 2023, a -204.79% decrease year-over-year.

Mereo Biopharma Group Plc ADR (MREO) Earnings per Share 2024

MREO earnings per share (TTM) was -$0.20 for the quarter ending December 31, 2023, a +40.72% growth year-over-year.

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.